Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleAdjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.
Author(s)Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M.
Journal, Volume, IssueJ Support Oncol. 2008 Mar;6(3):119-24.
Major outcome(s)Significant improvement of pain
IndicationAppetite loss/weight loss;Cancer;PainAbstract
MedicationNabilone

A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days' follow-up, in Edmonton Symptom Assessment System (ESAS) pain scores, and in total morphine-sulfate-equivalent (MSE) use after adjusting for baseline discrepancies using the propensity-score method. Secondary outcomes included other ESAS parameters and frequency of other drug use. Data from 112 patients (47 treated, 65 untreated) met criteria for analyses.The propensity-adjusted pain scores and total MSE use in nabilone-treated patients were significantly lower than were those found in untreated patients (both P < 0.0001). Other ESAS parameters that improved significantly in patients receiving nabilone were nausea (P < 0.0001), anxiety (P = 0.0284) and overall distress (total ESAS score; P = 0.0208). The nabilone group showed borderline improvement in appetite (P = 0.0516).When compared with those not taking nabilone, patients using this cannabinoid had a lower rate of starting nonsteroidal anti-inflammatory agents, tricyclic antidepressants, gabapentin, dexamethasone, metoclopramide, and ondansetron and a greater tendency to discontinue these drugs.

Route(s)Oral
Dose(s)
Duration (days)
Participants112 patients with advanced cancer
DesignOpen study
Type of publicationMedical journal
Address of author(s)Division of Palliative Medicine, William Osler Health Centre, University of Toronto, Canada. vincent.maida@utoronto.ca
Full text

[Back to Overview]  [IACM Homepage]


up